minimum bmi for glp 1 Who Qualifies Semaglutide GLP-1 Injections for Weight Loss? Before and after GLP-1: what

Wang, S

Suddenly, GLP-1s were contenders in heart disease prevention

September 2025: Eli Lilly announced complete Phase III ATTAIN-1 results for orforglipron, reporting meaningful weight loss and cardiometabolic improvements in adults with obesity or overweight

6.3 Clinical Symptoms That Should Prompt Assessment Patients on GLP-1 therapy should seek review if experiencing: Persistent fatigue Hair thinning beyond expected telogen shift Neurological symptoms (numbness, tingling) Muscle weakness Persistent vomiting Severe dietary restriction These symptoms are non-specific but warrant nutritional evaluation

The GLP-1 boom may be the first time a trillion-dollar drug class has collided with an outdated care system equal parts insulin , Viagra , and iPhone in how its reshaping health, culture, and capital